drugset / Trial / NCT01867762

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01867762 ↗

Phase 2 Completed 211 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2013-09-09
Primary completion
2014-08-06
Completion
2014-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ 49095397 Small molecule 400 ug Inhaled